Clairity provides an FDA-authorized AI platform that assesses future breast cancer risk using existing screening mammograms. This technology analyzes image data to generate a validated, equitable five-year risk assessment for women. The platform transforms standard diagnostic imaging into a predictive tool for early detection and prevention planning.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional breast cancer risk assessment relies on factors like age and family history, often missing subtle indicators present in mammograms. This can lead to delayed or inaccurate risk stratification, potentially resulting in late-stage diagnoses and disparities in care.
Solution
Clairity Breast is an FDA-authorized AI platform that analyzes existing screening mammograms to predict a woman's five-year future risk of developing breast cancer. The platform uses deep learning to identify subtle imaging features correlated with future cancer risk, providing a validated risk score to healthcare providers. This enables personalized follow-up care, early detection, and proactive intervention strategies. By incorporating diverse imaging data and clinical outcomes, Clairity aims to improve the accuracy and equity of breast cancer risk assessment.
Target Audience
The primary target audience includes healthcare providers, such as radiologists and oncologists, and health systems seeking to improve breast cancer screening accuracy and personalize patient care.
Features
- AI-driven analysis of screening mammograms to predict five-year breast cancer risk
- Deep learning models trained on diverse imaging data and clinical outcomes
- Identification of subtle imaging features undetectable by the human eye
- Validated five-year risk score delivered to healthcare providers
- Integration with existing clinical infrastructure for seamless workflow